Perna Ashley G, Ostler Daniel A, Ivan Doina, Lazar Alexander J F, Diwan A Hafeez, Prieto Victor G, Reed Jon A
Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.
J Cutan Pathol. 2007 May;34(5):381-5. doi: 10.1111/j.1600-0560.2006.00623.x.
Renal cell carcinoma marker (RCC-Ma) is a monoclonal antibody against a normal renal proximal tubule antigen. RCC-Ma expression is relatively specific for primary clear cell renal cell carcinoma. Its expression in cutaneous metastasis of renal cell carcinoma (MRCC) and other cutaneous clear cell lesions has not been studied.
One hundred and thirty-seven cutaneous clear cell lesions including eight xanthomas, 32 xanthelasmas, 25 xanthogranulomas, seven balloon cell nevi, six clear cell hidradenomas, 29 sebaceous adenomas, six sebaceous epitheliomas, eight sebaceous carcinomas, and 16 MRCC were examined using immunohistochemistry for the expression of RCC-Ma.
RCC-Ma was expressed in 10 of 16 (62.5%) MRCC, all with greater than 20% of cell labeling. Of these, 4 of 10 (40%) labeled with a membranous pattern and 6 of 10 (60%) labeled with both a membranous and a cytoplasmic pattern. RCC expression was not seen in any of the other clear cell lesions (p < 0.001). Furthermore, lack of expression in each of the other diagnostic groups was significant when each group was compared with the MRCCs (p < 0.01 at least for each group).
Our study demonstrates that RCC may be a valuable component of a panel of immunohistochemical markers when evaluating cutaneous clear cell lesions.
肾细胞癌标志物（RCC-Ma）是一种针对正常肾近端小管抗原的单克隆抗体。RCC-Ma表达对原发性透明细胞肾细胞癌具有相对特异性。其在肾细胞癌皮肤转移灶（MRCC）及其他皮肤透明细胞病变中的表达尚未见研究报道。
采用免疫组织化学方法检测137例皮肤透明细胞病变，包括8例黄瘤、32例睑黄瘤、25例黄色肉芽肿、7例气球细胞痣、6例透明细胞汗腺瘤、29例皮脂腺腺瘤、6例皮脂腺上皮瘤、8例皮脂腺癌及16例MRCC中RCC-Ma的表达情况。
16例MRCC中有10例（62.5%）表达RCC-Ma，所有表达病例的细胞标记率均大于20%。其中，10例中有4例（40%）呈膜性标记模式，10例中有6例（60%）呈膜性和胞质标记模式。在其他任何透明细胞病变中均未观察到RCC表达（p < 0.001）。此外，将其他各诊断组与MRCC组进行比较时，每组均无表达的差异具有统计学意义（每组至少p < 0.01）。
我们的研究表明，在评估皮肤透明细胞病变时，RCC可能是免疫组织化学标志物组合中的一个有价值的组成部分。
